Naess I A, Christiansen S C, Cannegieter S C, Rosendaal F R, Hammerstroem J
Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
J Thromb Haemost. 2006 Jan;4(1):44-9. doi: 10.1111/j.1538-7836.2005.01691.x.
We prospectively examined whether there is an association between elevated anticardiolipin antibody levels and the risk for a future first venous thrombosis (VT) in a general population. We studied this in a large population-based nested case-cohort study of 508 VT cases and 1464 matched control subjects from a cohort of 66,140 participants in the Health Study of Nord-Trøndelag in Norway. Venous thrombosis was validated using standardized criteria for venous thrombosis and pulmonary embolism. Prethrombotic serum anticardiolipin antibodies were measured by an enzyme-linked immunoassay. There was no association between elevated anticardiolipin antibody levels and subsequent venous thrombosis, overall or after stratification by sex, different age groups or idiopathic vs. secondary thrombosis. The overall odds ratio was 1.11 (95% CI: 0.71-1.74) for greater than vs. less than the 95th percentile of anticardiolipin antibody levels. In conclusion, in this general population sample elevated anticardiolipin antibody levels was not a risk factor for subsequent venous thrombosis.
我们前瞻性地研究了在普通人群中，抗心磷脂抗体水平升高与未来首次发生静脉血栓形成（VT）风险之间是否存在关联。我们在挪威北特伦德拉格健康研究中，对66140名参与者组成的队列中的508例VT病例和1464名匹配的对照对象进行了一项基于人群的大型巢式病例对照研究。静脉血栓形成采用静脉血栓形成和肺栓塞的标准化标准进行验证。血栓形成前血清抗心磷脂抗体通过酶联免疫吸附测定法进行检测。抗心磷脂抗体水平升高与随后的静脉血栓形成之间无关联，无论是总体情况，还是按性别、不同年龄组或特发性与继发性血栓形成进行分层后。抗心磷脂抗体水平高于第95百分位数与低于第95百分位数相比，总体比值比为1.11（95%CI：0.71-1.74）。总之，在这个普通人群样本中，抗心磷脂抗体水平升高不是随后静脉血栓形成的危险因素。
